Favorable results of rituximab in combination with CHOP in the front-line treatment of follicular lymphoma grade 3.

被引：0
|
作者：
Fayad, Luis [1 ]
Overman, Michael [1 ]
Pro, Barbara [1 ]
McLaughlin, Peter [1 ]
Samaniego, Felipe [1 ]
Younes, Anas [1 ]
Romaguera, Jorge Enrique [1 ]
Hagemeister, F. B. [1 ]
Kwak, Larry [1 ]
Rodriguez, Maria Alma [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.2770.2770
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2770
引用
收藏
页码：784A / 784A
页数：1
相关论文
共 50 条
  • [41] Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study
    Mondello, Patrizia
    Steiner, Normann
    Willenbacher, Wolfgang
    Cerchione, Claudio
    Nappi, Davide
    Mauro, Endri
    Ferrero, Simone
    Cuzzocrea, Salvatore
    Mian, Michael
    ONCOLOGIST, 2018, 23 (04): : 454 - 460
  • [42] Low-Intensity Fludarabine, Cyclophosphamyde, Rituximab (FCR) as Front-Line Treatment for Follicular Lymphoma. Efficacy and Toxicity Profile of the Oral Versus Intravenous Administration
    Marin-Niebla, Ana
    Rios-Herranz, Eduardo
    de la Cruz Vicente, Faatima, Jr.
    Cerezuela, Paula
    Falantes, Jose Francisco
    Martino, Mariluz
    Espigado, Ildefonso
    Ispizua, Alvaro Urbano
    BLOOD, 2009, 114 (22) : 1052 - 1053
  • [43] No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan
    Focosi, D.
    Macera, L.
    Ciabatti, E.
    Galimberti, S.
    Petrini, M.
    Carella, A. M.
    Pistello, M.
    Ceccherini-Nelli, L.
    Maggi, F.
    INFECTION, 2014, 42 (06) : 1065 - 1066
  • [44] No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan
    D. Focosi
    L. Macera
    E. Ciabatti
    S. Galimberti
    M. Petrini
    A. M. Carella
    M. Pistello
    L. Ceccherini-Nelli
    F. Maggi
    Infection, 2014, 42 : 1065 - 1066
  • [45] Treatment Outcomes for Follicular Lymphoma with Progression of Disease within 24 Months of Front-Line Therapy: A Systematic Review
    Siddiqui, Raheel S.
    Shahzad, Moazzam
    Ahmed, Saba
    Zaidi, Sara J.
    Shahid, Sara
    Chattha, Suneeba
    Khan, Cyrus
    Anwer, Faiz
    BLOOD, 2021, 138
  • [46] Fludarabine, Cyclophosphamide and Rituximab As First Line Treatment In Follicular Lymphoma
    Vicente, Fatima de la Cruz
    Cruz, Estrella Carrillo
    Rodriguez, Maria Sole
    Niebla, Ana Marin
    Herranz, Eduardo Rios
    Galiana, Maria Luz Martino
    Gonzalez, Jose Falantes
    Cuadrado, Isabel Montero
    Campos, Jose Gonzalez
    Tocino, Ildefonso Espigado
    Perez-Simon, Jose A.
    BLOOD, 2013, 122 (21)
  • [47] Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma
    Trotman, Judith
    Cheah, Chan Y.
    Marlton, Paula
    Opat, Stephen
    INTERNAL MEDICINE JOURNAL, 2019, 49 (04) : 422 - +
  • [48] Results of Interim PET/CT Imaging during Front-Line Induction in Follicular Lymphoma Do Not Predict Survival Outcomes
    Goldman, Max L.
    Kim, Chaejin
    Chen, Zhengjia
    Calzada, Oscar
    Churnetski, Michael C.
    Flowers, Christopher
    Cohen, Jonathon B.
    BLOOD, 2017, 130
  • [49] A randomized trial of fludarabine and mitoxantrone plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma.
    Zinzani, PL
    BLOOD, 2001, 98 (11) : 842A - 842A
  • [50] The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma
    Fowler, Nathan H.
    Nastoupil, Loretta
    De Vos, Sven
    Knapp, Mark
    Flinn, Ian W.
    Chen, Robert
    Advani, Ranjana H.
    Bhatia, Sumeet
    Martin, Peter
    Mena, Raul
    Davis, Richard Eric
    Neelapu, Sattva S.
    Eckert, Karl
    Ping, Jerry
    Co, Melannie
    Beaupre, Darrin M.
    Neuenburg, Jutta K.
    Palomba, M. Lia
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (04) : 650 - 660
12345